Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2014EMBO Molecular MedicineOpen Access

The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT‐TCF pathway responses in human cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAlice MelottiUniversity of GenevaCMChristophe MasDebiopharm (Switzerland)MKMonika KuciakPoznan University of Medical Sciences

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Melotti et al. (2014) studied this question.

synapsesocial.com/papers/6a8c32bbfe910689a2894749https://doi.org/10.15252/emmm.201404084
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lessons from Hereditary Colorectal Cancer1996 · 4,949 citations
  2. 2Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug2012 · 431 citations
  3. 3Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells2010 · 182 citations
  4. 4Loss of WNT‐TCF addiction and enhancement of HH‐GLI1 signalling define the metastatic transition of human colon carcinomas2010 · 92 citations
  5. 5Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling2014 · 223 citations